Last reviewed · How we verify
Apixaban steady-state
At a glance
| Generic name | Apixaban steady-state |
|---|---|
| Also known as | Eliquis steady-state |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition (PHASE4)
- Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers (PHASE1)
- Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4) (PHASE2)
- Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients (PHASE4)
- Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus (PHASE1)
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra (PHASE1)
- Triple vs. Dual Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixaban steady-state CI brief — competitive landscape report
- Apixaban steady-state updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI